Management Advisory Board

Mr. Stewart Roth
Management Advisory Board Chair

President and CEO of Guardian Chemicals Inc, Skyline Products Ltd, Varyx International, Sierra Chemicals Inc, Traxol Chemicals (RSA), and Vector Holdings Ltd
Stewart Roth is a successful Edmonton businessman with broad experience in the chemical industry. He is past Chair, Alberta Hospital Edmonton Foundation; Director of Northeast Capital Industrial Association (NCIA); Chair, NCIA Education Committee; and member, Synergy Networks, Edmonton. He is Chair of the Centennial Centre for Interdisciplinary Science Advisory Committee (a major new building for the Faculty of Science at the U of A), a member of the Curriculum Advisory Committee of the Department of Chemistry at the University of Alberta, and the Chair of the Alberta Glycomics Centre Management Advisory Board.

Dr. Yvan Guindon
Director of the Bio-Organic Chemistry Laboratory
Institut de Recherches Cliniques de Montréal

Dr. Guindon has held leading positions in major pharmaceutical enterprises, including Senior Director at Merck Frosst Canada and VP Research at Bio-Méga (now known as Boehringer Ingelheim Canada Ltd.). He completed his term of office as the Chief Executive Officer and Scientific Director of the Institut de Recherches Cliniques de Montréal, a position he held for 10 years during which the Institute experienced remarkable expansion (1994-2004). He is a member of the Departments of Chemistry at the Université de Montréal as well as the Department of Chemistry at McGill University. Dr. Guindon was elected to the Royal Society of Canada in 1990 and was named to the Order of Canada in 2005. In 2006, he received the Prix Lionel-Boulet, Prix du Québec. He was President-Elect of the Royal Society of Canada from 2006-2007, President from November 2007-2009 and past President from 2009 to 2011. He was the winner of the Alfred-Bader, Canadian Chemsitry Society in 2012 and received the insignia of Chevalier de l’ordre national du Québec in 2012.

Dr. Chang-Chun Ling
Principal Investigator
Associate Professor, Chemistry University of Calgary

Dr. Ling’s research resides in the area of organic synthesis with a particular emphasis on oligosaccharide synthesis, conjugation chemistry and cyclodextrin chemistry. He graduated from the University of Lanzhou with a B.Sc. degree in chemistry (1986). He then moved to Université de Paris Sud to pursue his graduate studies and obtained his Ph.D. degree in Organic Chemistry (1991). After several years of postdoctoral experience (University Colleague Dublin, Université Pierre et Marie Curie and University of Alberta), he joined Alberta Research Council by working on multiple collaborative projects with pharmaceutical companies (1996). He then moved back to University of Alberta to work in Prof. David Bundle’s group as a senior research associate by developing cancer immunotherapies based on gangliosides (1998-2006). In 2006, he was appointed as an assistant professor at the Department of Chemistry, University of Calgary, and currently, his is an associate professor at the department. His research group has extensive expertise in developing novel synthetic methodologies for important carbohydrates that have biosignificance; these include complex oligosaccharides that are involved in tumorigenesis, cancer metathesis, autoimmune conditions, bacterial toxin adhesion and bacterial and viral infection. Research in these areas has the potential to generate small molecular therapeutics and vaccines to treat cancer, infections and also autoimmune diseases such as multiple sclerosis. In addition, Dr. Ling’s group is heavily involved in the development of fundamental chemistries for cyclodextrins. Currently, they are working towards cyclodextrin-based technologies that can be used for drug delivery.

Mr. Barry Mehr
Vice President, Food & Fibre Alberta Innovates Technology Futures

Barry Mehr brings more than 50 years of experience and expertise in this industry sector and government to his new position. He began his career in food and agriculture in Ontario in the early 1960s, after completing his undergraduate degree in food chemistry. Barry spent 10 years working for Swift Canadian Company Ltd. in various sales and managerial positions before joining Canada’s public service. Between 1977 and 2009, Barry served the Government of Alberta as an Assistant Deputy Minister and Deputy Minister in various ministries, including Alberta Agriculture, Food and Rural Development (AAFRD), Economic Development, and Innovation and Science.
Barry currently is past Board Chair of the Board of Governors at Olds College. He also serves as a member of the Alberta Innovates Glycomics Centre of Excellence Management Advisory Board, the Board of Directors of the Alberta Agriculture and Food Council, the Board of Directors of Genome Alberta and a Founder and Board of Directors Member of Safe Food Canada- the Learning Partnership.

Barry’s Sector provides strategic support to various customers, including global consumers, distributors, processors and Government of Alberta agencies and regulators of Food, and Fibre products.. His group is also helping support the development of the Province’s food, agriculture and fibre value chains.

Dr. Jonathan Schaeffer
Dean of Science, University of Alberta

Jonathan Schaeffer began his term as Dean of Science on July 1, 2012. He is an internationally recognized researcher in the field of artificial intelligence. He is best known for using games as his experimental test bed. He became the dean of science after four years in the role of vice-provost and associate vice-president (information technology) at the U of A. Schaeffer’s research achievements led to a host of awards and honours. He received an E.W.R. Steacie fellowship from NSERC in 1997 for his influential games-related research. He is just one of a dozen Canadians ever named a Fellow of the American Association for Artificial Intelligence. He was a tier-1 Canada Research Chair (2002–2009) and is the iCORE Chair in High-Performance Artificial Intelligence Systems since 2001. In 2007, Schaeffer was elected a Fellow of the Royal Society of Canada.

Dr. Don Stanski
Global VP Quantitative Clinical Pharmacology, AstraZeneca

For over 30 years, Don Stanski has been a significant shaping force in Quantitative Clinical Pharmacology. Following medical school at the University of Calgary and Anesthesiology clinical training at Mass General Hospital, Dr. Stanski then studied clinical pharmacology/pharmacometrics with the late Lewis B. Sheiner at UCSF. He became a faculty member then Professor and Chairman in the Department of Anesthesia, Stanford University, California; after which Vice President of Scientific and Medical Affairs at Pharsight Corp. He spent 2 years at the FDA as scientific advisor to Janet Woodcock MD, Deputy Commissioner prior to his most recent appointment in 2006 as VP and Global Head, Modeling and Simulation at Novartis. Don’s unique blend of experience in academia, regulatory and industry is unparalleled enabling Don to shape the discipline of Clinical Pharmacology and Pharmacometrics. Dr. Stanski has over 100 publications and an appointment to the editorial board of Clinical Pharmacology & Therapeutics, and prior to that Anesthesiology and Journal of Pharmacokinetics and Biopharmaceutics. In 2014 Dr. Stanski joined AstraZeneca as Global VP Quantitative Clinical Pharmacology.

Dr. Robert Zamboni
Adjunct Professor of Chemistry, McGill University

Dr. Robert J. Zamboni, Ph.D. is an Adjunct Professor of Chemistry at McGill University. Dr. Zamboni was the Vice President of Research at Merck & Co., Inc., from June 1999 to 2005. He has 25 years of industry experience and is responsible for the chemistry of multiple approved drugs. Dr. Zamboni served as Senior Research Chemist of Merck & Co., Inc. He serves as a Member of Scientific Advisory Board for Link Medicine Corporation. Mr. Zamboni is a Member of Scientific Advisory Board of BELLUS Health (Innodia) Inc. and 3-V Biosciences, Inc. Dr. Zamboni is a Member of the American Chemical Society and is the recipient of numerous prestigious awards, including the Prix Galien and the Prix Lionel-Boulet, awarded by the Quebec government for contributions to the development of medicinal chemistry. Dr. Zamboni also received a Heroes’ of Chemistry Award from the American Chemistry Society in recognition of his work in discovering and developing Singulair, for the treatment of asthma. Dr. Zamboni’s career has been devoted to chemistry drug discovery which has resulted in many compounds in clinical development and over 114 publication and 28 patents. Mr. Zamboni received a BSc in Honours Chemistry and his PhD in Organic Synthesis from McGill University and following postdoctoral fellowships at the University of Pittsburgh and Yale University.